A Phase 3, Randomized, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) - ALUMMINATE RRMM
A Phase 3, Randomized, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) - ALUMMINATE RRMM
The purpose of this study is to evaluate the efficacy and safety of alnuctamab compared to standard of care regimens in participants with relapsed or refractory multiple myeloma (RRMM).
Inclusion Criteria
Participant is willing and able to adhere to the study visit schedule and other protocol requirements including bone marrow aspirations and/or biopsies and hospitalization during the first cycle.
Documented diagnosis of multiple myeloma (MM), and must:.
i) Received at least 1 but not more than 3 prior lines of anti-myeloma therapy.
ii) Received prior treatment with lenalidomide and an anti-CD38 monoclonal antibody (for at least 2 consecutive cycles).
iii) Achieved minimal response (MR) or better to at least 1 prior anti-myeloma therapy.
iv) Documented PD during or after their last anti-myeloma therapy or failure to achieve response.
Exclusion Criteria
Macquarie University, New South Wales 2109, Australia
Shimotsuga, Tochigi 321-0293, Japan
Koto, Tokyo 135-8550, Japan
Løenskog, Akershus 1474, Norway
El Palmar, Murcia, Murcia, Región de 30120, Spain
Stanbul, Istanbul 34214, Turkey (Türkiye)